Jul. 2 at 2:14 PM
$HRTX ZYNRELEF & APONVIE franchise growth
In my view, based on the charts and Heron's reaffirmed 2026 guidance, the only real question is how strong the upside will be.
This year, the reaffirmed guidance implies ~
$75–80M in combined ZYNRELEF and APONVIE revenue. Based on the current trend,
$110–135M combined by next year appears reasonable.
Favorable CINVANTI outcome: A stay pending appeal (preventing generic entry) or, even better, a settlement with Azurity, similar to the agreements with Mylan, Baxter, and Fresenius Kabi, combined with continued ZYNRELEF and APONVIE growth, could support a very high valuation.
Unfavorable outcome: If generics are allowed, erosion may begin in 2027. But even then, the other franchises could fairly reach
$110–130M and continue growing.
Based on this, I believe Heron remains a solid Bio company. The only question is how valuable it becomes - and that's why the opportunity here is so rare. Relatively safe investment, with a very significant upside.
